Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-1 of 1

Sort by

Sort Order Select

Journal Articles

Oral Rilzabrutinib, a Bruton Tyrosine Kinase Inhibitor, Showed Clinically Active and Durable Platelet Responses and Was Well-Tolerated in Patients with Heavily Pretreated Immune Thrombocytopenia

David J. Kuter, MD, Merlin Efraim, MD, Jiri Mayer, MD, Vickie McDonald, MD, Robert J. Bird, FRACP,FRCP,FRCPA,MBBS,MRCP, Thomas Regenbogen, MD, Mamta Garg, MD FRCP, FRCPath, Zane Kaplan, MBBS(Hons) BMedSc(Hons) PhDFRACP FRCPA, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-134932

Published: 2020